Erythropoietin use and the risk of stroke in patients on hemodialysis: A retrospective cohort study in Taiwan

Peir Haur Hung, Chih Ching Yeh, Chih Yen Hsiao, Chih Hsin Muo, Kuan Yu Hung, Kuen Jer Tsai

研究成果: 雜誌貢獻文章同行評審

摘要

BACKGROUND: Targeting higher hemoglobin levels with erythropoietin to treat anemia in patients with chronic kidney disease is associated with increased cardiovascular risk, including that of stroke. The risks of the subtypes of stroke, ischemic, hemorrhagic, and unspecified, following the administration of erythropoietin in patients with end-stage renal disease receiving hemodialysis remain unclear. METHODS AND RESULTS: Overall, 12 948 adult patients with end-stage renal disease treated during 1999 to 2010 who had undergone hemodialysis were included. The study end points were the incidences of stroke and its subtypes. We used Cox proportional hazards regression models to estimate hazard ratios (HRs) of stroke and its subtypes in erythropoietin recipients compared with nonrecipients. Patients in the erythropoietin cohort did not have an increased risk of stroke compared with those in the nonerythropoietin cohort (adjusted HR, 1.03; 95% CI, 0.92–1.15). Compared with patients in the nonerythropoietin cohort, the risks of ischemic, hemorrhagic, or unspecified stroke were not higher in patients in the erythropoietin cohort (adjusted HRs, 1.08 [95% CI, 0.93–1.26], 0.96 [95% CI, 0.78–1.18], and 1.03 [95% CI, 0.80–1.32], respectively). Increased risks of stroke and its subtypes were not observed with even large annual defined daily doses of erythropoietin (>201). CONCLUSIONS: Erythropoietin in patients receiving hemodialysis is not associated with increased risk of stroke or any of its subtypes.

原文英語
文章編號e019529
期刊Journal of the American Heart Association
10
發行號14
DOIs
出版狀態已發佈 - 七月 20 2021

ASJC Scopus subject areas

  • 心臟病學與心血管醫學

指紋

深入研究「Erythropoietin use and the risk of stroke in patients on hemodialysis: A retrospective cohort study in Taiwan」主題。共同形成了獨特的指紋。

引用此